Doxycycline in Lymphanioleiomyomatosis (LAM): a randomised double blind placebo controlled crossover trial

This study is testing whether doxycycline — an antibiotic that also has anti-inflammatory and anti-enzyme properties — can help slow the progression of lung disease in women with Lymphangioleiomyomatosis (LAM). LAM is a rare lung disease that primarily affects women and causes gradual destruction of lung tissue. This is a crossover trial, meaning participants will receive both the drug and a placebo at different times. You may be eligible if: - You are female and 18 years of age or older - You have been diagnosed with LAM confirmed by biopsy or CT scan - You have abnormal lung function consistent with LAM - You are able to provide written informed consent You may NOT be eligible if: - You are pregnant or breastfeeding, or not using adequate contraception - You have significant gastrointestinal disease that might affect drug absorption - You have uncontrolled systemic disease or significant kidney impairment - You have received an investigational drug in the past 30 days - You have previously had a lung transplant - You have chylous ascites or a pleural effusion large enough to affect breathing - You have had a pneumothorax in the past 2 months - You have a documented allergy to doxycycline or related medications Talk to your doctor about whether this trial might be right for you.